Pharmaceutical Executive March 14, 2025
Deal to acquire Covis is expected to expand Azurity’s portfolio across multiple complex dosage forms and key therapeutics areas.
Azurity Pharmaceuticals has completed its acquisition of Covis Pharma, making Covis a wholly owned subsidiary. Financial terms for the deal were not disclosed in a press release.
According to Azurity, the acquisition expands its portfolio across nine key therapeutic areas—cardiovascular, respiratory, central nervous system, endocrinology, gastrointestinal, hematology, immunology, anti-infectives, and oncology—as well as numerous complex dosage forms. Additionally, the acquisition is expected to enhance Azurity’s global presence in over 50 countries.1
“We are excited to welcome Covis Pharma to Azurity,” said Ronald Scarboro, CEO of Azurity, in a press release. “The efforts of colleagues at both companies, their devotion to overlooked...
Today's Sponsors
Today's Sponsor